Sucralfate NDC 66689-305

NDC codes

FDA NDC Directory

Product NDC (as listed)66689-305Labeler and product segments. Claims need a package NDC.

Product NDC at billing width66689-0305Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
66689-305-16	66689030516	1 BOTTLE, PLASTIC in 1 CARTON (66689-305-16) / 414 mL in 1 BOTTLE, PLASTICMarketed from Mar 15, 2022

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Sucralfate
Generic name (nonproprietary): sucralfate
Active ingredients: Sucralfate — 1 g/10mL
Dosage form: Suspension
Route: Oral
Labeler: VistaPharm, LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 211884
Marketing start: Mar 15, 2022
Listing expires: Dec 31, 2027
Other FDA classes: Organometallic Compounds (Chemical structure)
Identifiers: Product ID 66689-305_d88c8a64-33d7-4977-9371-2d51c2700589SPL ID d88c8a64-33d7-4977-9371-2d51c2700589SPL set ID cbfbe146-5d42-4a55-9050-df2b5581487aRxCUI 313123UNII XX73205DH5UPC 0366689305165
Pharmacologic class: Aluminum Complex

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N466689030516 followed by a unit qualifier and the quantity

Package 66689-0305-16. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Sep 2, 2026.

Indications (excerpt from the label)

INDICATIONS AND USAGE Sucralfate Oral Suspension is indicated in the short-term (up to 8 weeks) treatment of active duodenal ulcer.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 211884

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 211884
Product	Strength	Form · route	Labeler	Product NDC
Sucralfate	Sucralfate 1 g/10mL	SuspensionOral	PAI Holdings, LLC dba PAI Pharma	0121-0974
Sucralfatesucralfate oral suspension	Sucralfate 1 g/10mL	SuspensionOral	Major Pharmaceuticals	0904-7470
Sucralfate	Sucralfate 1 g/10mL	SuspensionOral	American Health Packaging	60687-738
Sucralfate	Sucralfate 1 g/10mL	SuspensionOral	Cardinal Health 107, LLC	55154-5790
Sucralfate	Sucralfate 1 g/10mL	SuspensionOral	ATLANTIC BIOLOGICALS CORP.	17856-0306